Current Neurology and Neuroscience Reports

, Volume 11, Issue 1, pp 89–96

Treatment of Myasthenia Gravis


DOI: 10.1007/s11910-010-0151-1

Cite this article as:
Kumar, V. & Kaminski, H.J. Curr Neurol Neurosci Rep (2011) 11: 89. doi:10.1007/s11910-010-0151-1


Myasthenia gravis (MG) is an antibody-mediated, neuromuscular transmission disorder, which ranges in clinical manifestations of ocular myasthenia that may be visually disabling to myasthenic crisis with patients suffering life-threatening respiratory insufficiency. MG also has pathophysiologic subgroups based on presence or absence of acetylcholine receptor or muscle-specific kinase antibodies and presence of thymoma. Cholinesterase inhibitors partially improve weakness, but the vast majority of patients require therapies that moderate the autoimmune attack. Mortality of MG has been reduced over the last century, but adverse effects of treatment compromise patient care and rigorous evidence to guide the clinician are lacking.


Myasthenia gravisOcular myastheniaAcetylcholine receptorCorticosteroidAzathioprineMycophenolate mofetilCyclosporineIntravenous immunoglobulinPlasma exchangeComplementAcetylcholine receptor antibodyThymectomyMuscle specific kinase

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Neurology & PsychiatrySaint Louis UniversitySt. LouisUSA